0000000000156901

AUTHOR

Chiara Ippolito

showing 2 related works from this author

Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy

2021

Background: Ponatinib (PON), a third-generation tyrosine kinase inhibitor (TKI), has proven cardiovascular toxicity, with no known preventing agents usable to limit such side effect. Sodium-glucose cotransporter type 2 (SGLT2) inhibitors are a new class of glucose-lowering agents, featuring favorable cardiac and vascular effects. Aims: We assessed the effects of the SGLT2 inhibitors empagliflozin (EMPA) and dapagliflozin (DAPA) on human aortic endothelial cells (HAECs) and underlying vasculo-protective mechanisms in an in vitro model of PON-induced endothelial toxicity. Methods and results: We exposed HAECs to PON or vehicle (DMSO) in the presence or absence of EMPA (100 and 500 nmol/L) or …

Physiologymedicine.drug_classCellPharmacologyAutophagy; Ponatinib; Sodium-glucose cotransporter type 2 (SGLT2) inhibitors; Tyrosine kinase inhibitors; Vascular toxicityTyrosine-kinase inhibitorFlow cytometrychemistry.chemical_compoundmedicineAutophagyHumansViability assayDapagliflozinCellular SenescencePharmacologyTyrosine kinase inhibitorsMatrigelmedicine.diagnostic_testChemistrySodiumImidazolesEndothelial CellsEndothelial stem cellPyridazinesmedicine.anatomical_structureGlucoseDiabetes Mellitus Type 2Sodium-glucose cotransporter type 2 (SGLT2) inhibitorsToxicityPonatinibMolecular MedicineVascular toxicity
researchProduct

Role of cyclooxygenase pathways in bowel fibrotic remodelling in a murine model of experimental colitis

2022

Abstract Objective Gut fibrosis occurs under chronic inflammation. This study examined the effects of different cyclooxygenase (COX) inhibitors on fibrosis in the inflamed colon. Methods Colitis was induced by 2,4-dinitrobenzenesulfonic acid (DNBS) in albino male Sprague–Dawley rats. After 6, 12 and 18 days, macroscopic and microscopic damage, collagen and elastic fibre content were examined. At day 6, pro-fibrotic factors (collagen I and III, hydroxyproline, fibronectin, matrix metalloproteinase-2 and -9), transforming growth factor-beta (TGF-β) signalling [TGF-β, Ras homolog gene family member A (RhoA), phosphorylated small mother against decapentaplegic (pSMAD)-2 and -6] and peristalsis …

TGF-βPharmacologyfibrosis cyclooxygenase inhibitor gutinflammatory bowel diseasefibrosiscyclooxygenase inhibitorgutPharmaceutical ScienceSMADCyclooxygenaseJournal of Pharmacy and Pharmacology
researchProduct